Corinthian Colleges Inc. (COCO)

Company Description
Corinthian Colleges, Inc. (Corinthian) is a post-secondary education company in the United States and Canada, serving the segment of the population seeking to acquire career-oriented education. As of June 30, 2010, the Company had a student enrollment of 110,580 and operated 101 schools in 25 states, and 17 schools in the province of Ontario, Canada. As of August 13, 2010 all of its schools operated under one of three national brands, Everest, WyoTech, or Heald. As of June 30, 2010, 101 out of 118 schools were operating under the Everest brand, six schools were operating under the WyoTech brand, and 11 schools were operating under the Heald brand. The Company offers a variety of diploma programs and associate's, bachelors and master's degrees through a single operating segment. Its training program areas include healthcare, criminal justice, mechanical, trades, business and information technology. On January 4, 2010, the Company completed its acquisition of Heald Capital, LLC.


Faizan's take
Corinthian Colleges Inc. (COCO) yesterday closed at $5.06 a share. My analysis of this stock shows that after a one year long downtrend now might be the time when COCO starts moving up. It can be expected to a fair degree of confidence that a good upward trend will be established soon and will continue for a few months.
Suggested price target $6.97 (37% gain).


NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.

Orexigen Therapeutics, Inc. (OREX)

Company Description
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Each of these product candidates is a combination of generic drugs, which it has systematically screened for synergistic central nervous system, or CNS, activity. Each of the components of its product candidates has already received regulatory approval and has been commercialized previously.


Faizan's take
OREX last closed at $3.34 a share. Recently it broke out of a well formed symmetric triangle. It has potential to give a decent profit within the next year.
Suggested price target $4.47 (34% gain).


NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points 

Agilysys Inc. (AGYS)

"UPDATE: As of 1st June 2011 I will just name my picks with a little company information. Background technical analysis for each stock will not be provided anymore. This is because writing detailed technical analysis is very time consuming which my busy schedule does not allow. 

Instead I will like to promote discussions in the comments section and would like to listen to your take on the recommended picks.

However, if you still want the background analysis feel free to ask in the comments section or through email."

Company Description

Agilysys, Inc. is a leading provider of innovative IT solutions to corporate and public-sector customers, with special expertise in select markets, including retail and hospitality. The company develops technology solutions — including hardware, software and services — to help customers resolve their most complicated IT needs. The company possesses expertise in enterprise architecture and high availability, infrastructure optimization, storage and resource management, and business continuity, and provides industry-specific software, services and expertise to the retail and hospitality markets. Headquartered in Solon, Ohio, Agilysys operates extensively throughout North America, with additional sales offices in the United Kingdom and in Asia. Agilysys has three reportable segments: Hospitality Solutions Group (“HSG”), Retail Solutions Group (“RSG”), and Technology Solutions Group (“TSG”). 

Faizan's take

Currently trading at $6.81 a share AGYS has potential to leap upto 20% in value over the next 6 months or so. Suggested price target is $8.29 (21% gain).

NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.  

Companhia de Bebidas das Americas ADS (ABV)

"UPDATE: As of 1st June 2011 I will just name my picks with a little company information. Background technical analysis for each stock will not be provided anymore. This is because writing detailed technical analysis is very time consuming which my busy schedule does not allow. 

Instead I will like to promote discussions in the comments section and would like to listen to your take on the recommended picks.

However, if you still want the background analysis feel free to ask in the comments section or through email. "

Company Description
Companhia de Bebidas das Américas—AmBev is the successor of Companhia Cervejaria Brahma (“Brahma”) and Companhia Antarctica Paulista Indústria Brasileira de Bebidas e Conexos (“Antarctica”), two of the oldest brewers in Brazil. Antarctica was founded in 1885. Brahma was founded in 1888 as Villiger & Cia. The Brahma brand was registered on September 6, 1888, and in 1904 Villiger & Cia. changed its name to Companhia Cervejaria Brahma. AmBev, a Brazilian sociedade anônima, was incorporated as Aditus Participações S.A. (“Aditus”) on September 14, 1998. AmBev is a publicly held corporation incorporated under the laws of the Federative Republic of Brazil.


Faizan's take

ABV currently at $31.54 is demonstrating very good technicals and can give a decent profit in the upcoming months. Suggested price target is $33.89 (7.5% increase).

NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.